



## Clinical trial results:

### **A PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLASMA EXCHANGE WITH 5% ALBUMIN IN BETA-AMYLOID PEPTIDE CLEARANCE IN CEREBROSPINAL FLUID, AND ITS EFFECTS IN PATIENTS WITH MILD-MODERATE ALZHEIMER'S DISEASE**

#### **Summary**

EudraCT number	2007-000414-36
Trial protocol	ES
Global end of trial date	07 March 2011

#### **Results information**

Result version number	v1 (current)
This version publication date	03 July 2016
First version publication date	03 July 2016

#### **Trial information**

##### **Trial identification**

Sponsor protocol code	IG0602
-----------------------	--------

##### **Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00742417
WHO universal trial number (UTN)	-

Notes:

##### **Sponsors**

Sponsor organisation name	Instituto Grifols S.A.
Sponsor organisation address	Can Guasch 2, Parets del Vallès, Spain, 08150
Public contact	Mireia Torres, Instituto Grifols S.A., +34 935712273, mireia.torres@grifols.com
Scientific contact	Mireia Torres, Instituto Grifols S.A., +34 935712273, mireia.torres@grifols.com

Notes:

##### **Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	07 March 2011
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	07 March 2011
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To determine whether plasma exchange with 5% human albumin is able to modify the concentration of beta-amyloid peptide in cerebrospinal fluid (CSF) in the treatment group of patients with Alzheimer's disease (AD).

Protection of trial subjects:

The study characteristics will be duly described to all subjects amenable to participation in the trial (or to the legal representatives in the case the patient is unable) - followed by the request for free and voluntary authorization. The subject and the accepted legal representative of the subject will be informed of the nature, purpose and procedures of the study, with a description of the possible risks involved.

Background therapy:

Receiving stable treatment with acetylcholine esterase inhibitors (AChEIs) for the previous three months prior to starting the trial.

Evidence for comparator:

No comparators were used in this study. The control group was subjected to simulated plasma exchanges (without invasive procedures).

Actual start date of recruitment	20 July 2007
Long term follow-up planned	Yes
Long term follow-up rationale	Safety, Efficacy
Long term follow-up duration	6 Months
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United States: 9
Country: Number of subjects enrolled	Spain: 33
Worldwide total number of subjects	42
EEA total number of subjects	33

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0

Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	17
From 65 to 84 years	25
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

2 weeks for screening and randomization of treatment and control group. Subjects were randomized in a 1:1 proportion.

After screening and randomization, followed:

3 weeks of intensive treatment with 2 PE/week

Followed by a 1,5 months (6 weeks) of maintenance treatment with 1 PE/week, and

3 months (12 weeks) of treatment with 1 PE/2weeks

### Pre-assignment

Screening details:

After obtaining informed consent, there was a screening period of 2 weeks of 1 or more visits for each patient.

### Pre-assignment period milestones

Number of subjects started	48 <sup>[1]</sup>
Number of subjects completed	39

### Pre-assignment subject non-completion reasons

Reason: Number of subjects	Screening Failure: 4
Reason: Number of subjects	Physician decision: 1
Reason: Number of subjects	Withdrawal by Legal Representative: 1
Reason: Number of subjects	Consent withdrawn by subject: 3

Notes:

[1] - The number of subjects reported to have started the pre-assignment period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: A total of 48 patients from 4 different centres were enrolled in the study, 42 of them were finally randomised: 21 patients were randomized to treatment and 21 patients to control. Of those, 39 subjects received at least 1 treatment. The overall study population has been considered to be the safety population (39 subjects) for age and gender purposes information.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Single blind <sup>[2]</sup>
Roles blinded	Subject, Carer

Blinding implementation details:

Neuropsychologists were also blinded.

The control group was subjected to simulated plasma exchanges (without invasive procedures). A gauze dressing was placed on the subclavicular region, affixing a catheter of characteristics similar to the catheters used in the treatment group, and procedures simulating plasma exchange were carried out.

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Control Group (Sham)

Arm description:

The control group was subjected to simulated plasma exchanges (without invasive procedures).

Arm type	Sham group
No investigational medicinal product assigned in this arm	
<b>Arm title</b>	Treatment Group

---

**Arm description:**

18 Plasma Exchanges using Albutein 5%:

- three weeks of intensive treatment with two plasma exchanges per week
- six weeks of maintenance treatment with one weekly plasma exchange
- three months of maintenance treatment with one plasma exchange every two weeks

---

Arm type	Experimental
Investigational medicinal product name	Albutein 5%
Investigational medicinal product code	B05AA01
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

---

**Dosage and administration details:**

The volume of each replacement was approximately that of the plasma volume of the subject as calculated from body weight, height and hematocrit (approximately 35-45 mL/kg, corresponding to a volume of 2500-3000 mL).

---

**Notes:**

[2] - The number of roles blinded appears inconsistent with a single blinded trial. It is expected that there will be one role blinded in a single blind trial.

Justification: This study is blind for patients, caregivers and raters.

---

<b>Number of subjects in period 1<sup>[3]</sup></b>	Control Group (Sham)	Treatment Group
Started	20	19
Intensive Period	20	19
Maintenance I Period	19	16
Maintenance II Period	19	16
Completed	19	16
Not completed	1	3
Consent withdrawn by subject	1	2
Adverse event, non-fatal	-	1

---

**Notes:**

[3] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: Thirty nine (39) started the treatment while only 35 completed all the study procedures (Per protocol population). The overall study population has been considered to be the safety population (39 subjects).

## Baseline characteristics

### Reporting groups

Reporting group title	Overall Study
Reporting group description:	
There were 42 enrolled subjects and 3 out of them did not start the Intensive Period (treatment period) because were withdrawn due to the following reasons: Withdrawal by legal representative, Withdrawal by Subject and Physician Decision.	

Reporting group values	Overall Study	Total	
Number of subjects	39	39	
Age categorical			
There were 42 enrolled subjects and 3 out of them did not start the Intensive Period (treatment period) because were withdrawn due to the following reasons: Withdrawal by legal representative, Withdrawal by Subject and Physician Decision.			
Units: Subjects			
Adults (18-64 years)	17	17	
From 65-84 years	22	22	
Age continuous			
There were 42 enrolled subjects and 3 out of them did not start the Intensive Period (treatment period) because were withdrawn due to the following reasons: Withdrawal by legal representative, Withdrawal by Subject and Physician Decision.			
Units: years			
arithmetic mean	67.7		
standard deviation	± 7.9	-	
Gender categorical			
There were 42 enrolled subjects and 3 out of them did not start the Intensive Period (treatment period) because were withdrawn due to the following reasons: Withdrawal by legal representative, Withdrawal by Subject and Physician Decision.			
Units: Subjects			
Female	30	30	
Male	9	9	

### Subject analysis sets

Subject analysis set title	FAS Population - Control Group
Subject analysis set type	Full analysis
Subject analysis set description:	
The efficacy analyses were performed with the FAS population which was defined as the set of subjects who were randomized and received at least three plasma exchange sessions during the intensive treatment phase (the three first weeks of treatment).	
Subject analysis set title	FAS Population - Treatment Group
Subject analysis set type	Full analysis
Subject analysis set description:	
The efficacy analyses were performed with the FAS population which was defined as the set of subjects who were randomized and received at least three plasma exchange sessions during the intensive treatment phase (the three first weeks of treatment).	

Reporting group values	FAS Population - Control Group	FAS Population - Treatment Group	
Number of subjects	19	18	

Age categorical			
There were 42 enrolled subjects and 3 out of them did not start the Intensive Period (treatment period) because were withdrawn due to the following reasons: Withdrawal by legal representative, Withdrawal by Subject and Physician Decision.			
Units: Subjects			
Adults (18-64 years)	10	6	
From 65-84 years	9	12	
Age continuous			
There were 42 enrolled subjects and 3 out of them did not start the Intensive Period (treatment period) because were withdrawn due to the following reasons: Withdrawal by legal representative, Withdrawal by Subject and Physician Decision.			
Units: years			
arithmetic mean	66.8	67.7	
standard deviation	± 9	± 6.6	
Gender categorical			
There were 42 enrolled subjects and 3 out of them did not start the Intensive Period (treatment period) because were withdrawn due to the following reasons: Withdrawal by legal representative, Withdrawal by Subject and Physician Decision.			
Units: Subjects			
Female	14	15	
Male	5	3	

## End points

### End points reporting groups

Reporting group title	Control Group (Sham)
Reporting group description: The control group was subjected to simulated plasma exchanges (without invasive procedures).	
Reporting group title	Treatment Group
Reporting group description: 18 Plasma Exchanges using Albutein 5%: <ul style="list-style-type: none"> <li>• three weeks of intensive treatment with two plasma exchanges per week</li> <li>• six weeks of maintenance treatment with one weekly plasma exchange</li> <li>• three months of maintenance treatment with one plasma exchange every two weeks</li> </ul>	
Subject analysis set title	FAS Population - Control Group
Subject analysis set type	Full analysis
Subject analysis set description: The efficacy analyses were performed with the FAS population which was defined as the set of subjects who were randomized and received at least three plasma exchange sessions during the intensive treatment phase (the three first weeks of treatment).	
Subject analysis set title	FAS Population - Treatment Group
Subject analysis set type	Full analysis
Subject analysis set description: The efficacy analyses were performed with the FAS population which was defined as the set of subjects who were randomized and received at least three plasma exchange sessions during the intensive treatment phase (the three first weeks of treatment).	

### Primary: Change from baseline in AB42 Cerebrospinal Fluid (CSF) Levels

End point title	Change from baseline in AB42 Cerebrospinal Fluid (CSF) Levels
End point description: Change in levels of A $\beta$ 1-42 in CSF in the period between baseline lumbar puncture (before the start of treatment) and lumbar puncture immediately after the end of the last plasma exchange (whenever this may be). Separate assays of A $\beta$ 1-42 were performed with Innotech and The Genetics Company commercial kits.	
End point type	Primary
End point timeframe: Baseline up to week 44.	

End point values	FAS Population - Control Group	FAS Population - Treatment Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	19	18		
Units: pg/mL				
least squares mean (confidence interval 95%)				
Innotest	-45.5 (-135.1 to 44.2)	75.3 (-20 to 170.5)		
The Genetics Company	-283 (-441.1 to -125)	-86.2 (-253.9 to 81.5)		

## Statistical analyses

<b>Statistical analysis title</b>	Statistical hypothesis testing
Statistical analysis description:	
The analysis of the primary efficacy variable (change in A $\beta$ 1-42 levels in CSF) was carried out by an analysis of covariance (ANCOVA), with the change from baseline in A $\beta$ 1-42 in CSF at the last available measurement as dependent variable, treatment group as factor and the baseline level of A $\beta$ 1-42 in CSF as a covariate. The model assessed was the following: $Y_i = \mu + T_i + X_i \text{ BASELINE} + \text{eit}$ .	
Comparison groups	FAS Population - Control Group v FAS Population - Treatment Group
Number of subjects included in analysis	37
Analysis specification	Pre-specified
Analysis type	other <sup>[1]</sup>
P-value	< 0.05 <sup>[2]</sup>
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Confidence interval	
level	95 %
sides	2-sided
Variability estimate	Standard deviation

Notes:

[1] - A calculation was made of the confidence intervals of the fitted means for each treatment group, and of the differences between them, based on the above analytical model.

[2] - The statistical tests were performed with a 5% significance level and were two-sided. In addition to the tests, two-sided 95% confidence intervals (95% CI) were reported.

### Secondary: P-Tau and Tau CSF Levels Throughout the Study.

End point title	P-Tau and Tau CSF Levels Throughout the Study.
End point description:	
Levels of Tau and P-tau in CSF throughout the treatment phase and the follow-up phase (week 44).	
End point type	Secondary
End point timeframe:	
Baseline, week 02, week 08, week 20, week 33 and week 44	

End point values	FAS Population - Control Group	FAS Population - Treatment Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	19	18		
Units: pg/mL				
arithmetic mean (standard deviation)				
P-Tau (baseline) (Albutein n=18; Control n=19)	79 ( $\pm$ 35.1)	87.7 ( $\pm$ 51.4)		
P-Tau (week 02) (n=16; n=19)	94.1 ( $\pm$ 46.7)	87.5 ( $\pm$ 43.8)		
P-Tau (week 08) (n=15; n=18)	78 ( $\pm$ 41.3)	78.9 ( $\pm$ 46.3)		
P-Tau (week 20) (n=15; n=18)	84.1 ( $\pm$ 36.8)	88.4 ( $\pm$ 42)		
P-Tau (week 33) (n=14; n=15)	78.7 ( $\pm$ 40.4)	91.9 ( $\pm$ 57.6)		
P-Tau (week 44) (n=14; n=14)	85.1 ( $\pm$ 46.5)	89.9 ( $\pm$ 54.5)		
Tau (baseline) (n=18; n=19)	589.6 ( $\pm$ 344.2)	571.2 ( $\pm$ 354.4)		
Tau (week 02) (n=16; n=19)	711 ( $\pm$ 388.8)	669.8 ( $\pm$ 496.8)		

Tau (week 08) (n=15; n=18)	526.3 (± 326.9)	482.2 (± 307.4)		
Tau (week 20) (n=15; n=18)	555.6 (± 308.3)	537.1 (± 253.5)		
Tau (week 33) (n=14; n=15)	483.5 (± 318.5)	539.5 (± 309.6)		
Tau (week 44) (n=14; n=14)	544.1 (± 347.4)	544.3 (± 299.4)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Aβ1–40 Plasma Levels Before and After Each Study Period (The Genetics Company)

End point title	Aβ1–40 Plasma Levels Before and After Each Study Period (The Genetics Company)
End point description:	Plasma levels of Aβ1–40 before and after the Intensive period, Maintenance period I, Maintenance period II and the Follow-up phase (using The Genetics Company commercial kits).
End point type	Secondary
End point timeframe:	Baseline, pre-plasma exchange 1 (PRE-PE1), post-plasma exchange 6 (POST-PE6), pre-plasma exchange 7 (PRE-PE7), post-plasma exchange 12 (POST-PE12), pre-plasma exchange 13 (PRE-PE13), post-plasma exchange 18 (POST-PE18), week 33 and week 44.

End point values	FAS Population - Control Group	FAS Population - Treatment Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	19	18		
Units: pg/mL				
arithmetic mean (standard deviation)				
Aβ1–40 Baseline (Albutein n=18; Control n=18)	126.7 (± 43.2)	121.3 (± 52.6)		
Aβ1–40 PRE-PE1 (Intensive) (n=18; n=19)	105.8 (± 47.7)	120.3 (± 57.1)		
Aβ1–40 POST-PE6 (Intensive) (n=15; n=19)	123.9 (± 53.7)	255.7 (± 98.4)		
Aβ1–40 PRE-PE7(Maintenance I) (n=14; n=17)	139.7 (± 41.8)	150.7 (± 51.3)		
Aβ1–40 POST-PE12 (Maintenance I) (n=14; n=18)	150.4 (± 54.4)	287.1 (± 98.6)		
Aβ1–40 PRE-PE13 (Maintenance II) (n=15; n=19)	129.6 (± 40.3)	150 (± 66)		
Aβ1–40 POST-PE18 (Maintenance II) (n=14; n=18)	135.4 (± 50.2)	245.9 (± 102)		
Follow up (33 week) (n=14; n=15)	136.9 (± 37.3)	153.3 (± 50.6)		
Follow up (44 week) (n=15; n=14)	147.1 (± 23.4)	146.7 (± 41.7)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: A $\beta$ 1–42 Plasma Levels Before and After Each Study Period (The Genetics Company).

End point title	A $\beta$ 1–42 Plasma Levels Before and After Each Study Period (The Genetics Company).
-----------------	---

End point description:

Plasma levels of A $\beta$ 1–42 before and after the Intensive period, Maintenance period I, Maintenance period II and the Follow-up phase (using The Genetics Company commercial kits).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, pre-plasma exchange 1 (PRE-PE1), post-plasma exchange 6 (POST-PE6), pre-plasma exchange 7 (PRE-PE7), post-plasma exchange 12 (POST-PE12), pre-plasma exchange 13 (PRE-PE13), post-plasma exchange 18 (POST-PE18 and week 44).

End point values	FAS Population - Control Group	FAS Population - Treatment Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	19	18		
Units: pg/mL				
arithmetic mean (standard deviation)				
A $\beta$ 1–42 Baseline (Albutein n=18; Control n=18)	33.7 ( $\pm$ 81.4)	2.8 ( $\pm$ 9.3)		
A $\beta$ 1–42 PRE-PE1 (Intensive) (n=18; n=19)	20.9 ( $\pm$ 58.4)	6.6 ( $\pm$ 16.3)		
A $\beta$ 1–42 POST-PE6 (Intensive) (n=15; n=19)	4.9 ( $\pm$ 11.8)	9.8 ( $\pm$ 15.6)		
A $\beta$ 1–42 PRE-PE7 (Maintenance) (n=14; n=17)	4.5 ( $\pm$ 12.9)	0 ( $\pm$ 0)		
A $\beta$ 1–42 POST-PE12 (Maintenance I) (n=14; n=18)	5.9 ( $\pm$ 14.3)	10.7 ( $\pm$ 15.9)		
A $\beta$ 1–42 PRE-PE13 (Maintenance II) (n=15; n=19)	8.2 ( $\pm$ 17.2)	6.9 ( $\pm$ 11.8)		
A $\beta$ 1–42 POST-PE18 (Maintenance II) (n=14; n=18)	7.1 ( $\pm$ 14.3)	8 ( $\pm$ 16.7)		
Follow up (44 week) (n=15; n=14)	10.2 ( $\pm$ 18.2)	1.7 ( $\pm$ 6.6)		

## Statistical analyses

No statistical analyses for this end point

**Secondary: A $\beta$ 1–42 Plasma Levels Before and After Each Study Period (Innotest).**

End point title	A $\beta$ 1–42 Plasma Levels Before and After Each Study Period (Innotest).
-----------------	---

End point description:

Plasma levels of A $\beta$ 1–42 before and after the Intensive period, Maintenance period I, Maintenance period II and the Follow-up phase (using Innotest commercial kits).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, pre-plasma exchange 1 (PRE-PE1), post-plasma exchange 6 (POST-PE6), pre-plasma exchange 7 (PRE-PE7), post-plasma exchange 12 (POST-PE12), pre-plasma exchange 13 (PRE-PE13), post-plasma exchange 18 (POST-PE18), week 33 and week 44.

End point values	FAS Population - Control Group	FAS Population - Treatment Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	19	18		
Units: pg/mL				
arithmetic mean (standard deviation)				
A $\beta$ 1–42 Baseline (Albutein n=18; Control n=18)	49.5 ( $\pm$ 43.7)	40.1 ( $\pm$ 77.1)		
A $\beta$ 1–42 PRE-PE1 (Intensive) (n=18; n=19)	33.4 ( $\pm$ 29.1)	20.4 ( $\pm$ 21.5)		
A $\beta$ 1–42 POST-PE6 (Intensive) (n=15; n=19)	45.4 ( $\pm$ 31.3)	29.1 ( $\pm$ 23.2)		
A $\beta$ 1–42 PRE-PE7 (Maintenance I) (n=14; n=17)	58.5 ( $\pm$ 68.1)	29.5 ( $\pm$ 30.9)		
A $\beta$ 1–42 POST-PE12 (Maintenance I) (n=14; n=18)	41.4 ( $\pm$ 35.5)	25.1 ( $\pm$ 21)		
A $\beta$ 1–42 PRE-PE13 (Maintenance II) (n=15; n=19)	51.2 ( $\pm$ 48.3)	36.4 ( $\pm$ 35.9)		
A $\beta$ 1–42 POST-PE18 (Maintenance II) (n=14; n=18)	45.3 ( $\pm$ 42.4)	37.1 ( $\pm$ 40.9)		
Follow up (33 week) (n=14; n=15)	10.2 ( $\pm$ 16.7)	10.1 ( $\pm$ 12.9)		
Follow up (44 week) (n=15; n=14)	11.7 ( $\pm$ 20.8)	11.3 ( $\pm$ 11.4)		

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Change From Baseline to Week 44 in Cognitive, Functional and Neuropsychiatric Scores (MMSE, ADAS-Cog, NPS)**

End point title	Change From Baseline to Week 44 in Cognitive, Functional and Neuropsychiatric Scores (MMSE, ADAS-Cog, NPS)
-----------------	--

End point description:

Change in the cognitive, functional and neuropsychiatric scores and overall development.

- MMSE: Mini Mental State Examination Score (range = 0 to 30, with lower values indicating impairment)
- ADAS-Cog: Alzheimer's Disease Assessment Scale, Cognitive Subscale (range = 0 to 70, with higher values indicating impairment)
- NPS (Neuropsychological battery): •SDMT (Symbol Digit Modalities Test, range = 0 to 110, with lower values indicating impairment), •SVF (Semantic Verbal Fluency Test, with a maximum of 44 words in 60 seconds), •PVF F, A and S (Phonetic Verbal Fluency Test, with a maximum of 44 words in 60 seconds),

- BNT (Boston Naming Test, with a maximum of 15 pictures), •RAVLT (Rey Auditory Verbal Learning Test, with 15 words the patient should listen and remind)
- CSDD (Cornell Scale for Depression in Dementia, 0 = none; 1 =mild or intermittent; 2 = severe)

End point type	Secondary
----------------	-----------

End point timeframe:

Change from baseline at week 44.

End point values	FAS Population - Control Group	FAS Population - Treatment Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	19	18		
Units: units on a scale				
arithmetic mean (standard deviation)				
MMSE (Albutein n=15; Control n=14)	-3.8 (± 5.9)	-1.7 (± 3.2)		
ADAS-Cog (n=15; n=14)	6.6 (± 10.5)	3.9 (± 6.2)		
NPS (SDMT) (n=15; n=14)	-0.5 (± 2.5)	1.3 (± 11.2)		
NPS (SVF) (n=15; n=14) (n=15; n=14)	-0.4 (± 3.8)	2.5 (± 3.2)		
NPS (PVF(F)) (n=15; n=14)	0.6 (± 3.8)	-0.2 (± 2.6)		
NPS (PVF(A)) (n=15; n=14)	0.2 (± 3.2)	0.2 (± 3.4)		
NPS (PVF(S)) (n=15; n=14)	-0.6 (± 3.3)	1.1 (± 1.8)		
NPS (BNT) (n=15; n=14)	0.3 (± 4.1)	1.7 (± 2.5)		
NPS (RAVLT Intermediate 1) (n=15; n=14)	-0.1 (± 2)	1.1 (± 1.9)		
NPS (RAVLT Intermediate 2) (n=15; n=14)	-1 (± 1.5)	0.3 (± 1.6)		
NPS (RAVLT Intermediate 3) (n=15; n=14)	-0.3 (± 2)	0.1 (± 2.1)		
NPS (RAVLT Intermediate 4) (n=15; n=14)	-0.9 (± 2.5)	-1.1 (± 1.8)		
NPS (RAVLT Intermediate 5) (n=15; n=14)	-1.4 (± 1.8)	-0.3 (± 2.1)		
NPS (RAVLT Delayed) (n=15; n=14)	0.1 (± 1)	0.5 (± 1.6)		
CSDD (patient) (n=10; n=7)	-2.1 (± 5.6)	-0.8 (± 2.9)		
CSDD (caregiver) (n=13; n=11)	1.8 (± 3.7)	1 (± 4.1)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline to Week 44 in Cognitive, Functional and Neuropsychiatric Scores (ADCS-ADL, NPI, CDR-Sb and

End point title	Change From Baseline to Week 44 in Cognitive, Functional and Neuropsychiatric Scores (ADCS-ADL, NPI, CDR-Sb and
-----------------	---

End point description:

Change in the cognitive, functional and neuropsychiatric scores and overall development.

- ADCS-ADL: Alzheimer's Disease Cooperative Study/Activities Of Daily Living (23 questions describing daily activity of the subject and requests the informer to describe the actions or behaviors observed. Increased autonomy associated with higher scores, maximum of 78 points)
- NPI: Neuropsychiatric Inventory Questions (12 symptom domains scored by frequency [range=0 to 4, higher values being more frequent] and severity [range=1 to 3, higher values being more severe], total

score is sum of frequency x severity of all domains)

- CDR-Sb: Clinical Dementia Rating (range=0 to 3, higher values being more severe)
- ADCS-CGIC: Alzheimer's Disease Cooperative Study/Clinical Global Impression of Change (7-point Likert scale, 0=not assessed, 1=marked improvement, 2=moderate improvement, 3=minimal improvement, 4=no change, 5=minimal worsening, 6=moderate worsening and 7=marked worsening)

End point type	Secondary
----------------	-----------

End point timeframe:

Change from baseline at week 44.

End point values	FAS Population - Control Group	FAS Population - Treatment Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	19	18		
Units: units on a scale				
arithmetic mean (standard deviation)				
ADCS-ADL (Albutein n=15; Control n=14)	-4.9 (± 10.9)	-7.1 (± 11.4)		
NPI (total score) (n=15; n=14)	-4 (± 13.7)	-1.7 (± 14.1)		
NPI (total distress) (n=15; n=14)	3.6 (± 6.4)	-2.1 (± 7.8)		
CDR Sb score (n=15; n=14)	1.4 (± 3.3)	1.7 (± 1.5)		
ADCS-CGIC (n=15; n=14)	1.2 (± 1.1)	1.5 (± 0.7)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Magnetic Resonance Imaging (MRI) Structural Changes Variations Versus Baseline

End point title	Magnetic Resonance Imaging (MRI) Structural Changes Variations Versus Baseline
-----------------	--

End point description:

Structural changes in volume of the hippocampus, posterior cingular area, and other associated areas by Magnetic Resonance Imaging (MRI). Three measurements were made (week -2 or -1, 20 and 44). It was measured the variations versus the baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 00 (baseline), week 20 and week 44

End point values	FAS Population - Control Group	FAS Population - Treatment Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	20 <sup>[3]</sup>	20 <sup>[4]</sup>		
Units: cubic centimeters (cc)				
arithmetic mean (standard deviation)				
Hippocampus L (week 00)	1.91 (± 0.48)	1.9 (± 0.41)		

Hippocampus L (week 20)	1.85 (± 0.4)	1.76 (± 0.45)		
Hippocampus L (week 44)	1.76 (± 0.39)	1.64 (± 0.43)		
Hippocampus R (week 00)	2.14 (± 0.38)	2.04 (± 0.41)		
Hippocampus R (week 20)	2.07 (± 0.32)	1.98 (± 0.41)		
Hippocampus R (week 44)	1.96 (± 0.34)	1.88 (± 0.35)		
Post Cingulate (week 00)	10.38 (± 0.8)	10.6 (± 1.34)		
Post Cingulate (week 20)	10.39 (± 0.8)	10.22 (± 1.58)		
Post Cingulate (week 44)	10.23 (± 1.06)	10.6 (± 1.48)		
Total Intracranial Volume (week 00)	1064.38 (± 130.29)	1034.38 (± 99.77)		
Total Intracranial Volume (week 20)	1042.7 (± 119.93)	990.31 (± 83.42)		
Total Intracranial Volume (week 44)	1026.51 (± 148.43)	985.43 (± 86.1)		

Notes:

[3] - 2 groups of patients analysed, treatment and control group, of 20 each group.

[4] - 2 groups of patients analysed, treatment and control group, of 20 each group.

### Statistical analyses

No statistical analyses for this end point

### Secondary: Variations in Hypoperfusion Based on Single Photon Emission Computed Tomography (SPECT)

End point title	Variations in Hypoperfusion Based on Single Photon Emission Computed Tomography (SPECT)
-----------------	---

End point description:

Percentage of patients with improved perfusion at the end of the study compared to their initial perfusion. Frontal, parietal and temporal lobes were evaluated from the quantified NeuroGam images. This rendered parametric images showed brain alterations with more than 2 standard deviations with respect to a normal data base. Initial parametric images were compared to the final ones and it was considered perfusion improvement those patients that showed less stretch and/or defect intensity.

End point type	Secondary
----------------	-----------

End point timeframe:

End of study.

End point values	FAS Population - Control Group	FAS Population - Treatment Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	20 <sup>[5]</sup>	20 <sup>[6]</sup>		
Units: percentage of improvement				
number (not applicable)				
Parietal	20	25		
Temporal	10	25		
Frontal	5	5		

Notes:

[5] - 2 groups of patients analysed, treatment and control group, of 20 each group.

[6] - 2 groups of patients analysed, treatment and control group, of 20 each group.

### Statistical analyses

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Primary criterion of safety was % of plasma exchange (PE) associated with at least one adverse event (AE) that may be related to the study procedure (adverse reaction).

Adverse event reporting additional description:

In addition, global consideration will be made of the percentage PE involving some AE, whether or not related to the procedure. Vital signs, anxiety and restlessness tests and the criterion of the investigator were also used to evaluate patient safety.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	13.1
--------------------	------

### Reporting groups

Reporting group title	Control Group
-----------------------	---------------

Reporting group description:

Control group followed the same schedule; however, they did not undergo plasma replacement (it was subjected to simulated plasma replacements)

Reporting group title	Treatment Group
-----------------------	-----------------

Reporting group description:

18 Plasma Exchanges using Albutein 5%:

- three weeks of intensive treatment with two plasma exchanges per week
- six weeks of maintenance treatment with one weekly plasma exchange
- three months of maintenance treatment with one plasma exchange every two weeks

<b>Serious adverse events</b>	Control Group	Treatment Group	
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 20 (10.00%)	3 / 19 (15.79%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Nervous system disorders			
Loss of consciousness			
subjects affected / exposed	0 / 20 (0.00%)	1 / 19 (5.26%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Partial seizures			
subjects affected / exposed	0 / 20 (0.00%)	1 / 19 (5.26%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Medical device complication			

subjects affected / exposed	0 / 20 (0.00%)	1 / 19 (5.26%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Hepatobiliary disorders</b>			
Cholangitis			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Infections and infestations</b>			
Otitis media			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Control Group	Treatment Group	
<b>Total subjects affected by non-serious adverse events</b>			
subjects affected / exposed	14 / 20 (70.00%)	18 / 19 (94.74%)	
<b>Vascular disorders</b>			
Hypertension			
subjects affected / exposed	2 / 20 (10.00%)	0 / 19 (0.00%)	
occurrences (all)	2	0	
<b>Surgical and medical procedures</b>			
Bunion operation			
subjects affected / exposed	0 / 20 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
Urinary cystectomy			
subjects affected / exposed	0 / 20 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
<b>General disorders and administration site conditions</b>			
Asthenia			
subjects affected / exposed	0 / 20 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
Catheter site haemorrhage			

subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 19 (5.26%) 1	
Fatigue subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	2 / 19 (10.53%) 2	
Pyrexia subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	1 / 19 (5.26%) 1	
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 19 (5.26%) 1	
Psychiatric disorders Aggression subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	1 / 19 (5.26%) 1	
Anxiety subjects affected / exposed occurrences (all)	2 / 20 (10.00%) 2	4 / 19 (21.05%) 4	
Confusional state subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 19 (5.26%) 1	
Delirium subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 19 (5.26%) 1	
Depression subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 19 (5.26%) 1	
Depressive symptom subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 19 (5.26%) 1	
Disinhibition subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 19 (5.26%) 1	
Insomnia			

subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 19 (5.26%) 1	
Investigations Weight decreased subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 19 (5.26%) 1	
Injury, poisoning and procedural complications Fall subjects affected / exposed occurrences (all)  Procedural dizziness subjects affected / exposed occurrences (all)	2 / 20 (10.00%) 2  0 / 20 (0.00%) 0	2 / 19 (10.53%) 2  1 / 19 (5.26%) 1	
Nervous system disorders Dementia Alzheimer's type subjects affected / exposed occurrences (all)  Dizziness subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0  0 / 20 (0.00%) 0	1 / 19 (5.26%) 1  1 / 19 (5.26%) 1	
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	2 / 20 (10.00%) 2	7 / 19 (36.84%) 7	
Eye disorders Ocular hypertension subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 19 (5.26%) 1	
Gastrointestinal disorders Abdominal pain subjects affected / exposed occurrences (all)  Diarrhoea subjects affected / exposed occurrences (all)  Vomiting	0 / 20 (0.00%) 0  2 / 20 (10.00%) 2	1 / 19 (5.26%) 1  1 / 19 (5.26%) 1	

subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 19 (5.26%) 1	
Skin and subcutaneous tissue disorders Photosensitivity reaction subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 19 (5.26%) 1	
Musculoskeletal and connective tissue disorders Back pain subjects affected / exposed occurrences (all)	2 / 20 (10.00%) 2	1 / 19 (5.26%) 1	
Muscle haemorrhage subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 19 (5.26%) 1	
Pain in extremity subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 19 (5.26%) 1	
Periarthritis subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 19 (5.26%) 1	
Infections and infestations Bronchitis subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 19 (5.26%) 1	
Device related infection subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	5 / 19 (26.32%) 5	
Nasopharyngitis subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	2 / 19 (10.53%) 2	
Respiratory tract infection subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 19 (5.26%) 1	
Urinary tract infection subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 19 (5.26%) 1	
Upper respiratory tract infection			

subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 19 (5.26%) 1	
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 19 (5.26%) 1	
Hypercalcaemia subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 19 (5.26%) 1	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
24 October 2007	(Spanish amendment only) 1. Increase of the sample size from 40 to 42 subjects to have 36 evaluable subjects. 2. To clarify the procedures and the simulation of the plasmapheresis and to detail the tests done at each study visit. 3. To summarize the secondary biomarkers for AD to be determined in each study period. 4. To detail the specific methodology for the neuropsychological tests. The RAV Learning Test has been detailed as well as the order and the scales at each visit. It has been also clarified the paper of the blinded evaluators who should administer the neuropsychological tests to the patients.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

None.

Notes: